Introduction Ventilator-associated pneumonia (VAP) is common; its prevalence has been
highlighted by the Covid-19 pandemic. Even young patients can suffer severe nosocomial …

Antibiotic resistance has emerged as a key determinant of outcome in patients with serious
infections along with the virulence of the underlying pathogen. Within the intensive care unit …

Guidelines published jointly by the American Thoracic Society and Infectious Diseases
Society of America endorse the practice of appropriate empirical antibiotic therapy for …

Despite progress in the diagnosis, prevention and therapy for hospital-acquired infections,
ventilator-associated pneumonia (VAP) continues to complicate the course of a significant …

Ventilator-associated pneumonia (VAP) remains an important clinical problem globally,
being associated with significant morbidity and mortality. As management of VAP requires …

Ventilator‐associated pneumonia (VAP) is the most common infectious complication in
patients receiving mechanical ventilation and accounts for exorbitant use of resources in the …

Introduction: Ventilator-associated pneumonia (VAP) is a common and potentially fatal
complication of mechanical ventilation that is often caused by multidrug-resistant (MDR) …

Introduction: Ventilator-associated pneumonia (VAP) is a distinct clinical entity characterized
by an onset after 48 hours of the application of mechanical ventilation (MV). Protocols exist …

Diagnostic and treatment strategies in ICU patients with ventilator-associated pneumonia
(VAP) remain controversial, largely because of the paucity of well-controlled comparison …

This review summarizes the rationale for using or not using combinations of antibiotics to
treat ventilator-associated pneumonia (VAP). Patients suffering from VAP require empirical …